Compare BLZE & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLZE | STRO |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.8M | 524.8M |
| IPO Year | 2021 | N/A |
| Metric | BLZE | STRO |
|---|---|---|
| Price | $7.70 | $25.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $7.60 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 2.6M | 255.3K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $145,835,000.00 | N/A |
| Revenue This Year | $10.16 | N/A |
| Revenue Next Year | $10.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.27 | N/A |
| 52 Week Low | $3.26 | $0.67 |
| 52 Week High | $10.86 | $43.85 |
| Indicator | BLZE | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 75.30 | 30.61 |
| Support Level | $7.02 | $23.43 |
| Resistance Level | $8.29 | $27.96 |
| Average True Range (ATR) | 0.62 | 3.47 |
| MACD | 0.01 | -1.79 |
| Stochastic Oscillator | 57.98 | 0.40 |
Backblaze Inc offers a cloud storage platform designed to help businesses and consumers store, use, and protect their data. The company delivers its services through the Backblaze Storage Cloud platform, a purpose-built, web-scale software architecture operating on commodity hardware. Backblaze's offerings include B2 Cloud Storage, an Infrastructure-as-a-Service (IaaS) solution, and Computer Backup, a Software-as-a-Service (SaaS) solution. Its customer base includes individuals, developers, MSPs, small and medium-sized businesses, and large enterprises across industries, academic institutions, government agencies, and other enterprises. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Canada, and other markets.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.